Neuroscientific Biopharmaceuticals Ltd has released a press release.
Successful Clinical Results Achieved under Special Access
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Neuroscientific Biopharmaceuticals
- Trading Halt
- Fourth Patient Commences StemSmart MSC Treatment
- 2025 Annual Report & Appendix 4E
- Previous StemSmart Studies Support Renal Transplantation
- Experienced Cell Therapy Executive Appointed CEO
Later from Neuroscientific Biopharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Remarkable Results from Patients treated with StemSmart
- 2026 Annual Report & Appendix 4E
- Leading CRO Appointed for Phase 2 Crohn's Trial
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals